|
Priyanka's Biotech Briefing
Distilled Bio uses AI to process and generate content for you. Verify important details using the linked sources.
AI-generated briefing: FDA clears the first pediatric ML4 gene therapy trial; UniQure seeks approval for Huntington’s treatment as CAR-T studies face safety pauses.
The top 10 stories from Wed Sep 2, 2026 07:04 AM to Thu Sep 3, 2026 07:04 AM
Generated September 3, 2026 at 7:04 AM
|
|
|
#1 Capricor, Replimune illustrate why FDA must listen to rare disease specialists Published 2026-09-03 FDA advisory committee meetings for Capricor Therapeutics and Replimune highlighted differing patient outcomes and renewed calls for greater specialization in agency reviews. Covered by: biospace.com |
#2 Ultragenyx’s Angelman therapy fails Phase 3 trial in setback for Published 2026-09-03 Ultragenyx said its experimental antisense oligonucleotide therapy failed a Phase 3 trial for Angelman syndrome, hindering efforts to develop a treatment for the rare neurodevelopmental disorder. Covered by: endpoints.news, statnews.com |
#3 BridgeBio’s MFN Pact Exempts Orphan Products, Highlighting Deals Bespoke Nature Published 2026-09-02 BridgeBio’s most-favored-nation agreement exempts orphan products, illustrating how pharmaceutical companies tailor such deals to their specific needs. Covered by: insights.citeline.com |
#4 FDA leaders project enhanced scrutiny of foreign data Published 2026-09-02 FDA leaders are strengthening oversight of foreign clinical-trial data, amid concerns from lawmakers and industry about China’s expanding role in drug research. Covered by: endpoints.news, biospace.com |
#5 Updated US FDA Therapeutic Equivalence Guidance Allows Faster 505(b)(2) Rating Requests Published 2026-09-02 The FDA’s final therapeutic equivalence guidance may accelerate therapeutic-equivalence rating requests and automatic substitution for certain 505(b)(2) drugs. Covered by: insights.citeline.com |
#6 UniQure, after setbacks, seeks FDA approval of Huntington’s gene therapy Published 2026-09-02 UniQure is seeking FDA approval for its Huntington’s disease gene therapy after a turbulent year involving setbacks and U.S. regulators. Covered by: biopharmadive.com |
#7 Teva says gluten challenge study succeeds in celiac disease Published 2026-09-02 Teva reported that a single injection of its experimental antibody reduced intestinal damage in people with celiac disease during daily gluten exposure. Covered by: endpoints.news |
#8 FDA Allows First Gene Therapy Clinical Trial for Ultra-Rare Pediatric Neurodegenerative Disease Published 2026-09-02 The FDA allowed the first gene therapy clinical trial for children with ultra-rare Mucolipidosis Type IV, according to the ML4 Foundation. Covered by: prnewswire.com |
#9 Novartis’ Rhapsido cuts MS progression in Phase 3 trial, teeing up Roche battle Published 2026-09-02 Novartis plans to seek expanded approval for remibrutinib in relapsing multiple sclerosis by next year, following Roche’s fenebrutinib in the BTK inhibitor race. Covered by: biospace.com |
#10 Novartis’ and BMS’ paused CAR T trials, RevMed’s pancreatic cancer approval, more MFN deals Published 2026-09-02 Novartis and Bristol Myers Squibb paused CAR-T trials over safety concerns, while Revolution Medicines gained early FDA approval for a pancreatic cancer drug and BioNTech halted an mRNA trial. Covered by: biospace.com |
